Literature DB >> 26000922

Quality of life in 188 patients with myasthenia gravis in China.

Yongxiang Yang1, Min Zhang1, Jun Guo1, Shan Ma1, Lingling Fan1, Xianni Wang1, Chuan Li1, Peng Guo1, Jie Wang1, Hongzeng Li1, Zhuyi Li1.   

Abstract

Myasthenia gravis (MG) is a kind of chronic autoimmune disease which can weaken patients' motor function and, furthermore, produce negative impact on the health-related quality of life (HRQoL). The primary purpose of this research was to evaluate factors that might affect the HRQoL of MG patients. A cross-sectional clinical research was carried out including 188 successive patients with MG. Myasthenia Gravis Foundation of America (MGFA) classification and Quantitative Myasthenia Gravis (QMG) score were applied to assess the severity of the disease. The Medical Outcome Survey 36-Item Short-Form Health Survey (SF-36) was used to estimate the HRQoL. Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS) were utilized to measure the depression and anxiety symptom. Factors may influence the HRQoL of MG patients include age, educational level, occupation, the situation of the thymus, the type of MG and generalized myasthenia gravis (GMG), the severity of the disease and the psychological disorder. Higher QMG and HARS scores were two significant factors that can prognosticate lower Physical Composite Score (PCS) and Mental Composite Score (MCS), while older age was just a significant factor which has prognostic value for lower PCS. The results of this research may have a potential guiding significance for the clinical treatment strategy and improve the quality of life in patients with MG consequently. In addition to the treatment of physical symptoms, the psychological symptoms such as anxiety and depression should be concerned as well.

Entities:  

Keywords:  SF-36; health-related quality of life; myasthenia gravis

Mesh:

Year:  2015        PMID: 26000922     DOI: 10.3109/00207454.2015.1038712

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  The Impact of the Coronavirus Disease-2019 Pandemic on the Psychological Status and Quality of Life of Myasthenia Gravis Patients.

Authors:  Aleksandar Stojanov; Jelena Stojanov; Vuk Milosevic; Marina Malobabic; Goran Stanojevic; Milos Stevic; Gordana Djordjevic
Journal:  Ann Indian Acad Neurol       Date:  2020-05-08       Impact factor: 1.383

Review 2.  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature.

Authors:  Nathaly Garzón-Orjuela; Laura van der Werf; Laura Catalina Prieto-Pinto; Pieralessandro Lasalvia; Camilo Castañeda-Cardona; Diego Rosselli
Journal:  Intractable Rare Dis Res       Date:  2019-11

Review 3.  Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence.

Authors:  Yanjun Liu; Xiangqi Tang
Journal:  Front Psychiatry       Date:  2018-09-25       Impact factor: 4.157

4.  Factors associated with quality of life of people with Myasthenia Gravis.

Authors:  Ansuk Jeong; Ju-Hong Min; Yu Kyoung Kang; Juhyeon Kim; Misong Choi; Jin Myoung Seok; Byung Joon Kim
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

5.  Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients.

Authors:  Lu Yu; Li Qiu; Hao Ran; Qian Ma; Ya-Ru Lu; Wei-Bin Liu
Journal:  World J Psychiatry       Date:  2022-03-19

6.  Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales.

Authors:  Laura Diez Porras; Christian Homedes; Maria Antonia Alberti; Valentina Velez Santamaria; Carlos Casasnovas
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

7.  Burden of disease in myasthenia gravis: taking the patient's perspective.

Authors:  Sophie Lehnerer; Jonas Jacobi; Ralph Schilling; Ulrike Grittner; Derin Marbin; Lea Gerischer; Frauke Stascheit; Maike Krause; Sarah Hoffmann; Andreas Meisel
Journal:  J Neurol       Date:  2021-11-20       Impact factor: 6.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.